HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER
Clinical trials for HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug takes on T-DXd in breast cancer showdown
Disease control Not yet recruitingThis phase 2 trial tests whether a new drug, trastuzumab-rezetecan, works as well as the established drug T-DXd in shrinking HER2-positive breast tumors before surgery. About 68 women with early or locally advanced breast cancer will receive one of the two drugs for 8 cycles, the…
Matched conditions: HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New Double-Antibody attack aims to wipe out breast cancer before surgery
Disease control Not yet recruitingThis study tests whether a new drug combination (HLX87 plus HLX22 or pertuzumab) works better than standard chemotherapy before surgery for people with HER2-positive early or locally advanced breast cancer. About 817 participants will be randomly assigned to one of three treatmen…
Matched conditions: HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC